Bio-Path Holdings (NASDAQ: BPTH) stock soared during intraday trading Monday after the company announced promising interim results from its Phase 2 study of prexigebersen.
Bio-Path Holdings revealed encouraging interim findings from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for acute myeloid leukemia (AML) treatment at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, on June 1, 2024.
In an oral presentation, the company shared data demonstrating that prexigebersen continues to exhibit favorable tolerability and compelling efficacy outcomes in two reporting cohorts. These cohorts encompassed newly diagnosed AML patients and those with refractory/relapsed AML, with both groups surpassing outcomes achieved with frontline therapy.
Peter Nielsen, Chief Executive Officer of Bio-Path, expressed gratitude for the opportunity to present the company’s data at ASCO, emphasizing the significance of the findings and the urgent need for improved treatment options for AML patients. He stated,
“We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients.”
Nielsen also reaffirmed the company’s commitment to advancing the study, expressing confidence in Prexigebersen’s potential to positively impact the lives of AML patients facing limited treatment alternatives.
Bio-Path Holdings (NASDAQ: BPTH) Stock Movement
On Monday, BPTH stock surged 56.80%, closing at $3.23, marking a 59.11% increase for the week. The trading volume was 56,969,664 shares, significantly higher than the average daily volume of 2.32 million.
